


Devyser

Lower sequencing costs



Note: 1) Moore's law refers to the empirical relationship between the number of transistors on a microchip, which doubles every two years, while the cost of computers is halved.

Our vision

A world where personalized medicine is universally available thanks to simplified and reliable genetic tests



This is Devyser

Who we are


A specialised diagnostic kits and software provider for complex genetic testing within three focus areas to clinical diagnostic labs

What we do

Develop, produce and commercialise genetic test kits and software to guide targeted cancer therapies, to enable rapid diagnosis of hereditary diseases, as well as post-transplant follow-up


How we do it

Provide solutions that are easy to implement, maintain, and use resulting in substantial time and cost savings for the customer



Track record of double-digit growth

SEKm



~2.5 million

Sold tests to date
Proven products

~78%

Gross margin LTM Q1 2022
High gross margins

+45

Countries covered
Global reach

28

CE-IVD products launched
Track record of innovation

Focus on three attractive markets

Market	1 Hereditary diseases		2 Oncology		3 Post-transplantation monitoring	
Target areas	Reproductive health	Mendelian disorders	Hereditary cancer	Therapy selection	Post-transplant follow-up	
Target diseases	<ul style="list-style-type: none"> Rapid prenatal testing for chromosomal disorders (e.g. Down syndrome) Haemolytic disease (NIPT for Fetal RHD status) 	<ul style="list-style-type: none"> Thalassemia Cystic fibrosis 	<ul style="list-style-type: none"> Mutations in the breast cancer genes (BRCA 1 and 2) Hereditary breast and ovarian cancer (HBOC) genes Lynch syndrome Hereditary non-polyposis colorectal cancer (HNPCC) 	<ul style="list-style-type: none"> BRCA HBOC 	<ul style="list-style-type: none"> Onco No 1 Onco No 2 Onco No 3 	<ul style="list-style-type: none"> Stem cell transplant Solid organ transplant
Market	3.1 EURbn TAM 30% SAM of TAM +12% SAM growth (2020-2026E) 58% of total TAM 2020		850 EURm TAM 29% SAM of TAM +12% SAM growth (2020-2026E) 16% of total TAM 2020		1.4 EURbn TAM 7% SAM of TAM +19% SAM growth (2020-2026E) 26% of total TAM 2020	

% of net sales

Attractively positioned in the DNA test kit value chain

Dvysr[®]



THIRD-PARTY



Dvysr[®]



DNA test kits

Sequencing instrument

Data analysis

+ "Razor blade" business model

✗ Capital equipment

+ Recurring revenue potential

+ Recurring revenue potential

✗ One-time sale


+ SaaS model

Devysr's test kits are instrument agnostic and can be adapted to leading DNA sequencing instruments

Solves challenges in genetic testing

Traditional solutions - time-consuming with multiple steps


Complex multi-step and multi-tube process



- ✗ High amount of DNA required
- ✗ 1-2 days hands-on time
- ✗ 4-14 days total time including sequencing and data analysis
- ✗ Long onboarding of lab personnel

Devysr - easy-to-use single-tube solution

Simple 3-step single-tube process



- + Low amount of DNA and no pre-processing required
- + 45 minutes hands-on time
- + 1-2 days total time including sequencing and data analysis
- + Quick onboarding of lab personnel

Source: Company information.


Direct sales force and distributor network

Direct markets


- Austria
- Denmark
- Germany
- Italy
- Norway
- Sweden
- Switzerland

Go-direct initiatives

- North America
- UK
- Benelux
- Spain
- France




Growth strategy



Financial targets

Metric	Target	Q1 2022 Outcome	2021 Outcome	Historical performance
Revenue growth	<ul style="list-style-type: none"> Devyser's growth target is to achieve an annual organic growth in excess of 30% 	33.2%	42.3%	37% CAGR 2015 - 2021
Gross margin	<ul style="list-style-type: none"> Devyser targets to achieve a gross margin in excess of 80% in the medium-term (3-5 years) 	83.0%	76.9%	73.9% Average 2018 - 2021
EBIT-margin	<ul style="list-style-type: none"> Devyser's target is to prioritize investments in the organization to support growth and achieve an operating margin (EBIT) above 20% in the medium-term (3-5 years) 	Neg	Neg	Neg Average 2018 - 2021

Sales and gross margin per quarter



IPO and share issue on Dec. 10, 2021

- Base offering SEK 300 million
- Overallotment option SEK 48 million

Shareholders	No of shares	Share, %
Rutger Arnhult, via company	3 850 907	24,2
Swedbank Robur	1 378 200	8,7
Fjärde AP-fonden	1 361 300	8,6
Berenberg Asset Management acting on behalf of Univ. Inv. Fund	1 000 000	6,3
Ferd	1 000 000	6,3
Anders Hedrum (founder and CTO), private and via company	775 020	4,9
Ulf Klangby (founder and deputy CEO), private and via company	706 200	4,5
Dan Heuzenberger (founder and CMO), private and via company	547 680	3,5
Deka	420 000	2,7
Alpcot AB	372 900	2,4
Åsa Riisberg, via company	258 300	1,6
Lopus Alpha	215 000	1,4
Others (approx ca 1 000 shareholders)	3 994 562	25,2
Total	15 880 069	100,0

1) Before transaction costs.



Key attractions

- Specialised provider of advanced genetic test kits combined with software adapted to the leading DNA sequencing platforms
- Proven business model with high revenue growth and profitability
- Validated genetic test portfolio with tangible value proposition
- Addressing large and growing markets
- De-risked strategy for accelerated profitable growth